MyFinsight
Home
Blog
About
Aurinia Pharmaceuticals Inc. (AUPH)
Aurinia Pharmaceuticals Inc. (AUPH)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from the sale and matur...
Proceeds from issuance of common...
Net income
Others
Negative Cash Flow Breakdown
Purchase of common shares under ...
Purchases of investments
Tax withholding payments related...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net income
37,414
34,355
210,794
31,551
Deferred income tax
11,110
9,277
-176,194
-
Share-based compensation
2,839
-866
6,728
5,919
Amortization and depreciation
4,834
4,816
4,864
4,865
Foreign exchange (gain) loss on revaluation of monoplant finance lease liability
561
416
-367
-53
Net amortization of premiums and discounts on investments
1,881
2,319
2,335
2,625
Non-cash write-down of inventory
-
-
0
-
Other, net
2,663
-581
5,052
-720
Accounts receivable, net
-8,037
7,721
10,726
-9,363
Inventory
-1,259
720
897
-1,710
Prepaid expenses and other current assets
5,981
-950
-4,582
4,166
Other noncurrent operating assets
0
-
0
0
Accounts payable
-2,799
-652
1,099
-1,098
Accrued expenses and other liabilities
561
-5,592
13,122
-641
Deferred revenue
624
1,081
-482
-997
Operating lease liabilities
-227
-214
-202
-205
Cash flows from operating activities
52,566
32,560
45,668
44,449
Proceeds from the sale and maturities of investments
100,000
109,000
145,349
93,500
Purchases of investments
23,764
127,041
182,032
107,207
Upfront lease payments
-
-
0
0
Net cash and cash equivalents acquired in acquisition of kezar
-5,212
-
-
-
Purchases of property, equipment and intangible assets
0
39
72
65
Cash flows from investing activities
81,448
-18,080
-36,755
-13,772
Purchase of common shares under share repurchase plan
38,715
36,165
0
8,671
Payments of principal portion of monoplant finance lease liability
3,405
3,653
3,487
3,448
Proceeds from issuance of common shares for equity awards
58,441
713
1,607
1,993
Proceeds from issuance of common shares under espp
363
-
355
0
Tax withholding payments related to net settlements of equity awards
11,874
14,580
364
364
Cash flows from financing activities
4,810
-53,685
-1,889
-10,490
Net increase (decrease) in cash, cash equivalents and restricted cash
138,824
-39,205
7,024
20,187
Cash, cash equivalents and restricted cash, beginning of the period
41,008
80,213
73,189
83,433
Cash, cash equivalents and restricted cash, end of the period
179,832
-
-
-
Cash and cash equivalents
179,732
-
-
-
Restricted cash
100
-
-
-
Total cash, cash equivalents and restricted cash
179,832
41,008
80,213
73,189
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from the sale and
maturities of investments
$100,000K
(-60.83%↓ Y/Y)
Net income
$37,414K
(-16.59%↓ Y/Y)
Deferred income tax
$11,110K
Accounts receivable, net
-$8,037K
(-326.59%↓ Y/Y)
Proceeds from issuance of
common shares for...
$58,441K
(451.85%↑ Y/Y)
Net cash and cash
equivalents acquired in...
-$5,212K
Amortization and
depreciation
$4,834K
(-50.27%↓ Y/Y)
Share-based compensation
$2,839K
(39.78%↑ Y/Y)
Inventory
-$1,259K
(-117.31%↓ Y/Y)
Deferred revenue
$624K
(-87.88%↓ Y/Y)
Accrued expenses and
other liabilities
$561K
(103.27%↑ Y/Y)
Proceeds from issuance of
common shares under...
$363K
(-9.48%↓ Y/Y)
Cash flows from
investing activities
$81,448K
(358.63%↑ Y/Y)
Cash flows from
operating activities
$52,566K
(15.43%↑ Y/Y)
Cash flows from
financing activities
$4,810K
(105.13%↑ Y/Y)
Canceled cashflow
$23,764K
Canceled cashflow
$14,112K
Canceled cashflow
$53,994K
Net increase
(decrease) in cash, cash...
$138,824K
(556.19%↑ Y/Y)
Purchases of investments
$23,764K
(-89.99%↓ Y/Y)
Prepaid expenses and
other current assets
$5,981K
(217.14%↑ Y/Y)
Accounts payable
-$2,799K
(-49.28%↓ Y/Y)
Other, net
$2,663K
(164.45%↑ Y/Y)
Net amortization of
premiums and discounts on...
$1,881K
(-63.96%↓ Y/Y)
Foreign exchange (gain)
loss on revaluation...
$561K
(106.06%↑ Y/Y)
Operating lease
liabilities
-$227K
(42.53%↑ Y/Y)
Purchase of common shares
under share...
$38,715K
(-56.74%↓ Y/Y)
Tax withholding
payments related to net...
$11,874K
(31.41%↑ Y/Y)
Payments of principal
portion of monoplant...
$3,405K
(-45.09%↓ Y/Y)
Buy us a coffee